drugset / Trial / NCT00222170

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the production of mucin in GERD/RE subjects before and after 8 weeks of treatment with rabeprazole.

Timeline

Start
2005-05
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg